1 |
Storer, B. E. (1989). Design and analysis of phase I clinical trials, Biometrics, 45, 925-937.
DOI
ScienceOn
|
2 |
Chevret, S. (1993). The continual reassessment method in cancer phase I clinical trials, A simulation study, Statistics in Medicine, 12, 1093-1108.
DOI
ScienceOn
|
3 |
Dixon, W. J. and Mood, A. M. (1948). A method for obtaining and analyzing sensitivity data, Journal of the American Statistical Association, 43, 109-126.
DOI
ScienceOn
|
4 |
Goodman, S. N., Zhurak, M. L. and Piantadosi, S. (1995). Some practical improvements in the continualreassessment method for phase I studies, Statistics in Medicine, 14, 1149-1161.
DOI
ScienceOn
|
5 |
Korn, E. L., Midthune, D., Chen, T. T., Rubinstein, L. V., Christian, M. C. and Simon, R. M. (1994). Acomparison of two phase I trial designs, Statistics in Medicine, 13, 1799-1806.
DOI
ScienceOn
|
6 |
Lee, N. M. and Kim, D. (2012). Two-stage maximum tolerated dose estimation by stopping rule in phase I clinical trials, Journal of the Korean Statistical Society, 19, 57-64.
DOI
|
7 |
O'Quigley, J. and Chevret, S. (1991). Method for dose finding studies in cancer clinical trials: A review and results of a Monte Carlo study, Statistics in Medicine, 10, 1647-1664.
DOI
ScienceOn
|
8 |
Simon, R., Freidlin, B., Rubinstein, L., Arbuck, S.G. and Collins, J. (1997). Accelerated Titration Designs for Phase I Clinical Trials in Oncology, Journal of the National Cancer Institute, 89, 1138-1147.
DOI
ScienceOn
|